1,2,3,4-tetrahydroisoquinoline has been researched along with 3-methoxytyramine in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Abe, K; Miyatake, T; Ren, J; Sano, T; Shinohara, T; Taguchi, K; Utsunomiya, I; Wasai, T | 1 |
Antkiewicz-Michaluk, L; Romańska, I; Wąsik, A | 1 |
Antkiewicz-Michaluk, L; Białoń, M; Wąsik, A; Żarnowska, M | 1 |
3 other study(ies) available for 1,2,3,4-tetrahydroisoquinoline and 3-methoxytyramine
Article | Year |
---|---|
Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Cell Count; Disease Models, Animal; Dopamine; Dopamine Antagonists; Drug Interactions; Homovanillic Acid; Hydroxyindoleacetic Acid; Hypokinesia; Immunohistochemistry; Isoquinolines; Levodopa; Male; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Neurotoxins; Parkinsonian Disorders; Serotonin; Stereoisomerism; Substantia Nigra; Tetrahydroisoquinolines; Tyrosine 3-Monooxygenase | 2001 |
Comparison of the Effects of Acute and Chronic Administration of Tetrahydroisoquinoline Amines on the In Vivo Dopamine Release: A Microdialysis Study in the Rat Striatum.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Male; Microdialysis; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Rats, Wistar; Tetrahydroisoquinolines; Time Factors | 2016 |
Pro-cognitive effect of 1MeTIQ on recognition memory in the ketamine model of schizophrenia in rats: the behavioural and neurochemical effects.
Topics: Animals; Antipsychotic Agents; Brain; Corpus Striatum; Dopamine; Excitatory Amino Acid Antagonists; Exploratory Behavior; Ketamine; Male; Microdialysis; Motor Activity; Nootropic Agents; Norepinephrine; Rats; Rats, Sprague-Dawley; Rats, Wistar; Recognition, Psychology; Schizophrenia; Tetrahydroisoquinolines; Treatment Outcome | 2020 |